Saumur

Cannabinoid hyperemesis syndrome (CHS) causes severe abdominal pain and vomiting in people who use cannabis regularly. It is often relieved by hot showers, which helps with diagnosis. The prevalence of CHS in France is not well known, but a previous study found a low rate among emergency patients with unexplained abdominal pain. Since cannabis is widely used in France, this study aims to estimate how common CHS is among patients visiting emergency departments in Maine et Loire for abdominal pain or vomiting. This is an observational, prospective, multicenter study enrolling adult patients aged 18 to 65 who come to emergency departments for abdominal pain or vomiting for the first time during the study period. Participants complete a questionnaire using a QR code or paper form while at the emergency department. Those who report regular cannabis use (at least weekly for 6 months) are followed up by phone three months later to check symptoms, recurrences, treatments, and cannabis use status. Researchers will measure how many patients are diagnosed with CHS after ruling out other causes. The inclusion period will last 12 months, with each CHS-positive patient followed for about 3 months. The study will also record medical treatments and symptom changes. The total study duration is 15 months, focusing on better understanding CHS incidence and patient outcomes in emergency settings.

Philadelphia-negative myeloproliferative neoplasms (MPNs) are disorders of the blood stem cells that cause too many mature myeloid cells to be made. These disorders include polycythemia vera, essential thrombocythemia, prefibrotic primary myelofibrosis, and primary myelofibrosis. They often have genetic mutations that activate cell growth pathways, but the reasons for differences between types are not fully understood. This research focuses on monocytes and macrophages, immune cells that may play a role in how these diseases develop and vary. The study involves analyzing the monocytes from patients' blood samples to identify their characteristics. Researchers will look at surface markers, cytokine levels, and gene expression to create detailed profiles or "signatures" of these cells. This examination aims to understand how monocytes differ among the MPN subtypes and how they might contribute to disease features. Participants will provide blood samples for this testing. Researchers will measure diagnostic criteria based on the World Health Organization 2016 guidelines for different MPN diagnoses. The study assesses how monocyte profiles relate to disease type and progression. Patients must consent to participate and to have their data included in related research databases, and the study tracks clinical information and immune cell features to gain insights for future treatments.